Schizophrenia is a common psychiatric disorder with a complex genetic etiology. To understand the genetic basis of this syndrome in Portuguese Island populations, we performed a genome-wide scan of 29 families with schizophrenia, which identified a single region on 5q31-5q35 with strong linkage (NPL ¼ 3.09, P ¼ 0.0012 at D5S820). Empirical simulations set a genome-wide threshold of NPL ¼ 3.10 for significant linkage. Additional support for this locus in schizophrenia comes from higher-density mapping and mapping of 11 additional families. The combined set of 40 families had a peak NPL ¼ 3.28 (P ¼ 0.00066) at markers D5S2112-D5S820. These data and previous linkage findings from other investigators provide strong and consistent evidence for this genomic region as a susceptibility locus for schizophrenia. Exploratory analyses of a novel phenotype, psychosis, in families with schizophrenia and bipolar disorder detected evidence for linkage to the same markers as found in schizophrenia (peak NPL ¼ 3.03, P ¼ 0.0012 at D5S820), suggesting that this locus may be responsible for the psychotic symptoms observed in both diseases. Molecular Psychiatry (2004) 9, 213-218. doi:10.1038/ sj.mp.4001418 Published online 30 December 2003 Schizophrenia is a complex genetic disorder that is found worldwide. Many studies have demonstrated a strong familial genetic component with an approximately 10-fold increased risk for illness in first-degree relatives.
1 This is supported by twin studies that detected a concordance rate of 41-65% for schizophrenia in monozygotic twin pairs. 2 It is likely that multiple susceptibility loci contribute to this syndrome, and the potential role of gene-gene interactions in pathogenesis must also be considered. Furthermore, the contribution of individual environmental factors to schizophrenia cannot yet be quantified, although their individual effects do not appear to play a role comparable to the genetic background.
2 Despite these difficulties, some consistent linkage signals have emerged, suggesting that true susceptibility loci for schizophrenia have been identified (for a review, see Sklar . Recently, specific genes, although not specific polymorphisms, have been identified for several of the linkage regions. [6] [7] [8] [9] [10] Geographically and genetically isolated populations have played a key role in disease gene identification. 11 We are studying island populations of Portuguese descent to identify the genetic basis of schizophrenia. The Azorean islands are a nine-island archipelago located in the mid-Atlantic and the island of Madeira is 300 km off the coast of western Africa. Madeira and the Azorean islands had no native population and were settled in the early 1400s almost exclusively by the Portuguese. The settlement of the Azores was a methodical program over a number of years, although the total number of founder families is not known (Costa, 1991) . The current population of Azores is 249 000, and of Madeira is 300 000. While the full genetic distinctiveness of this population is not yet known and there are no reports of an excess of recessive Mendelian disorders, the population structure was instrumental in the successful mapping of the gene for Machado-Joseph Disease. 12 Church records on the islands are excellent and provide a mechanism for tracing families for many generations. The islands are served by a modern centralized health system. Our close collaboration with all of the clinicians on the islands allows us unprecedented access to patients and their families. A combination of these factors contributes to the importance of this population to our study. For example, in the course of this study, we have been able to collect a populationbased sample with nearly complete ascertainment of schizophrenia cases on the largest Azorean island of São Miguel (population ¼ 150 000).
A genome-wide scan of schizophrenia was performed on families from the Azores, Madeira and the city of Coimbra on the Portuguese mainland. Families were chosen for genotyping, based on the presence of an affected relative pair from a total of 108 schizophrenia families ascertained to date. The initial genome scan of schizophrenia included 21 families from the Azorean Islands, four from Madeira and four from Coimbra on the Portuguese mainland. Best estimate diagnoses were made according to DSM-IV by two independent blinded researchers after review of clinical information, Diagnostic Interview for Genetic Studies (DIGS), Operational Criteria Checklist for Psychotic Illness (OPCRIT) 13 and written narratives. A single narrow phenotypic model was chosen that included only schizophrenia and schizoaffective disorder-depressed type. Genotyping data were available for the analysis for 185 family members, of which 67 members were affected with either schizophrenia (n ¼ 64) or were schizoaffective disorder-depressed (n ¼ 3) for 366 microsatellite markers, with an average intermarker spacing of 9.6 cM.
Nonparametric linkage analysis of the data was performed using GENEHUNTER 2.0.
14 Nominally significant P-values were obtained in two regions, a single marker on chromosome 1 at marker D1S1622 (NPL ¼ 2.12, P ¼ 0.018) and four consecutive markers on chromosome 5q31-35 spanning approximately 28 cM. The maximum NPL in this region was located at D5S820 (NPL ¼ 3.09, P ¼ 0.0012) (Figure 1 ). Recent evidence suggests that thresholds established assuming full pedigree and genotyping information are overly conservative under the experimental conditions encountered in a typical primary 10 cM genome scan with respect to marker density, percentage of missing genotypes and availability of parental information. 15 In order to estimate the strength of the observations of linkage in our initial 10 cM genome scan, we performed genome-wide simulations under the model that no genes were present that affected disease risk. We designed simulations that matched our real data in all relevant variables: family structure, individuals available for genotyping, percentage of genotypes achieved in those individuals available for genotyping, marker spacing and marker heterozygosity. These simulations were performed using GENSIM (MJD, unpublished), a pedigree genotype simulator that attaches to GENEHUNTER. [16] [17] [18] In all, 100 complete genome scans were simulated, and these show that the threshold for suggestive linkage (ie, the level of linkage expected once per genome scan by chance) is an NPL ¼ 2.25 and the threshold for declaring significant linkage (ie, linkage expected once per 20 genome scans by chance for a genomewide P ¼ 0.05) is NPL ¼ 3.10.
In order to obtain further confidence in our schizophrenia linkage signal on 5q, we genotyped an additional 14 microsatellite markers on chromosome 5 in the original 29 schizophrenia families, with an average intermarker distance of 4.2 cM. The resulting peak NPL score increased to 3.55 (P ¼ 0.00026) at markers D5S2011-D5S820 (Figure 2 ). Simulations were performed as described above, incorporating this increased density of markers, and indicated an NPL of 3.6 representing genome-wide significance.
Given the modest number of pedigrees analyzed, the strength of the linkage signal is consistent with a degree of disease homogeneity within this geographically isolated population. The ability to accomplish almost full ascertainment of cases on the Azorean Island of São Miguel as well as the use of a narrow phenotypic definition also likely contributed to our findings.
We were able to collect a second independent sample of 11 Portuguese Island families (Azores, n ¼ 7; Madeira, n ¼ 4) that were typed for markers on 5q. Fine mapping data were available on 43 family members, of which 29 members were affected with either schizophrenia (n ¼ 26) or were schizoaffective disorder-depressed (n ¼ 3). A peak NPL for these new families was obtained at marker D5S2011 (NPL ¼ 2.12, P ¼ 0.02). The peak NPL score in all the 40 families combined was obtained at D5S2112-D5S820 (NPL ¼ 3.28, P ¼ 0.00066) with nominally significant P-values obtained across a B35 cM region from D5S816 to D5S1456 (Figure 2 ). Despite the observation that the linkage signal in the second sample of 11 families is not notably stronger (the maximum NPL is located within the broad overall peak, but approximately 15 Mb centromeric), the overall proximity of the two signals strengthens the results. Furthermore, the two signals likely represent the same susceptibility locus, since the limited ability of linkage analyses to precisely localize linkage has been demonstrated. Of course, it is possible that more than one susceptibility locus is present in this region.
Several independent groups have presented evidence for linkage on 5q (Table 1) . Of these, two large studies on isolated populations find linkage within 10 Mb of our signal. 19, 20 The ability to detect a consistent linkage in these isolated populations of European ancestry may have been enhanced by greater genetic and/or environmental homogeneity. Similarly, despite the lack of evidence for clear founding effects, the Icelandic population has proven useful for identifying a schizophrenia disease gene that is also present in other populations. 9, 10 While one meta-analysis of schizophrenia linkage studies did not find evidence for linkage to 5q, 21 this lack of linkage may have occurred because the analysis did not contain a number of studies. 19, 20, [22] [23] [24] More recently, using the rank-based genome-scan meta-analysis method of Wise and Lewis, 25 data from 20 genome scans were analyzed together, and identified a 30 cM bin containing the proximal portion of 5q31-5q35 as meeting the criteria for genome-wide significance. 26 It is important to note that these findings did not include results from our study, but that the identified 30 cM bin overlaps the peak of our signal. Taken together, the strength of the data in this report, the number of other studies with linkage in the region and a meta-analysis, all strongly suggest that one or more genes for schizophrenia lie on 5q.
One special feature of the Azorean sample collection is that it includes uniform methods for collection of patients with schizophrenia or bipolar disorder. Since the relationship between schizophrenia and psychotic bipolar disorder is supported by family studies, 27, 28, [29] [30] [31] linkage analysis, 21, 27, 32 neurophysiologic studies 33 and brain imaging studies, [34] [35] [36] we expanded the phenotype to include psychosis. The psychosis phenotype was defined as part of the best estimate diagnostic process for all patients being evaluated for inclusion in the genome scan of schizophrenia, and for a related genome scan of bipolar disorder from the same geographical area (data not presented). Subjects were required to have credible positive psychotic symptoms (hallucinations and/or delusions). Families were included in the analysis of psychosis if two or more members had had an episode of psychosis (n ¼ 45) regardless of diagnosis. All the 29 families from the schizophrenia genome scan were included. In all, 14 families from an ongoing collection of bipolar disorder were included. Two further families were included that were previously excluded from the schizophrenia genome scan, because we were unable to classify them as predominantly schizophrenia families (equal number of affecteds had schizophrenia and bipolar disorder).
Psychosis data were available for a total of 389 family members, of whom 116 were affected individuals. A total of 67 affected individuals were previously included in the schizophrenia genome scan (58%). The remaining 49 individuals with a history of psychosis also met the criteria for the following diagnoses: schizophrenia (n ¼ 6), bipolar I (n ¼ 32), schizoaffective-manic (n ¼ 4), bipolar II (n ¼ 1), recurrent major depression (n ¼ 4), major depression single episode (n ¼ 1) and other (n ¼ 1). Nonparametric linkage analysis of the data using GENEHUNTER 2.0 is shown in Figure 1 . The strongest signal was obtained for those markers on chromosome 5 that were previously detected in schizophrenia (peak NPL ¼ 3.03, P ¼ 0.0012, marker D5S820). Nominally significant findings were obtained in six additional regions (D1S1622, NPL ¼ 1.72, P ¼ 0.045; D6S1031, NPL ¼ 1.82, P ¼ 0.037; D10S1423, NPL ¼ 2.15, P ¼ 0.017; D11S2371; NPL ¼ 1.93, P ¼ 0.029; D20S471, NPL ¼ 2.13, P ¼ 0.018). Of these regions, chromosome 10p has been identified in previous scans of both bipolar disorder and schizophrenia. NPL scores in the sample of 14 bipolar families showed a peak NPL at D5S2057 (NPL ¼ 1.77, P ¼ 0.04), approximately 25 Mb centromeric to D5S820 overlapping the peak region detected in several schizophrenia linkage scans (Table 1) . However, replication in further larger samples will be needed to confirm the presence of a psychosis locus on chromosome 5q.
In summary, we report strong evidence for linkage in schizophrenia to chromosome 5q31-35 in a population-based sample of Portuguese Island families. The strength of findings in this region makes it a solid susceptibility locus for schizophrenia, and suggests that positional cloning approaches are warranted. We also present the first reported genome scan using psychosis as a heritable symptom shared between bipolar disorder and schizophrenia, and identify a potential linkage to the same region of chromosome 5 as seen in schizophrenia. This result is consistent with the hypothesis that there may be shared genes for vulnerability to psychosis in schizophrenia and bipolar disorder.
Methods

Subjects
Families with two or more affected individuals were ascertained from systematic screening of all treating clinicians, treatment facilities, social services and extensive family interviews. In the Azores, all the four psychiatric hospitals and the two general hospitals participated in the study. Similarly, in Madeira, both psychiatric hospitals and the general hospital participated. On the mainland, families were identified by our collaborators at the University of Coimbra. Informed consent was obtained for participation in the genetic and family studies. Collection of blood and family history information was approved by all of the appropriate Institutional Review Boards. On the islands, families were ascertained if both of the proband's parents and all four of the grandparents were native to the islands. Diagnoses were made from data obtained with the Diagnostic Interview for Genetic Studies (DIGS). 37 Interviews were performed at the site of the subjects' clinical care, in their homes, or at an alternate site of the subject's choice. Interviewers were highly trained psychiatrists, psychologists or social workers. Inter-rater reliability was assured by careful training and evaluation of each interviewer, prior to the study onset and annually throughout. Periodically, reliability was assessed by having a set of 12 subjects assessed independently by interviewers from different study sites and by a senior supervisor. The chance-corrected inter-rater agreement k was high for the diagnoses of schizophrenia, bipolar disorder and schizoaffective disorder (k ¼ 0.9-0.94). Items related to the diagnosis of schizotypy showed slightly less agreement (kB0.75). Thorough clinical narratives were completed for all subjects. Best estimate diagnoses according to DSM-IV were made by two independent blinded researchers after review of clinical information, DIGS, Operational Criteria Checklist for Psychotic Illness (OPCRIT) 13 and written narratives. All cases where there was disagreement were reviewed by a third senior psychiatrist blind to the status of the case (MT Pato, MD).
Genotyping
Genomic DNA was extracted from whole blood, according to standard protocols. A genome-wide screen was performed using a modified set of the Cooperative Human Linkage Centre Screening Set, version 6.0. Fluorescently labeled markers were detected on an ABI-3700 and allele sizes were called using Genotyper v.3.6 software. The marker map positions were based on the Marshfield map. PED-MANAGER software was used for allele binning and inheritance analysis. For fine mapping on chromosome 5, 14 additional markers were genotyped as described above in the original 29 families. These same 14 markers were also genotyped in the additional 11 families.
Data analysis
14 To establish a threshold for suggestive and significant genome-wide linkage, simulations were performed. These simulations were performed using GENSIM (MJD, unpublished), a pedigree genotype simulator that attaches to GENEHUNTER [16] [17] [18] that matched our data set in relevant variables (family structure, individuals available for genotyping, percentage of genotypes achieved in those individuals available for genotyping, marker spacing and marker heterozygosity).
